HIGHLIGHTS
- who: Oleg V. Markov et al. from the Institute of Chemical Biology and Fundamental Medicine SB RAS, Lavrentieva Ave8, Novosibirsk, Russia MV. Lomonosov Institute of Fine Chemical Technologies, MIREA-Russian Technological University have published the paper: Dendritic Cell-Derived Artificial Microvesicles Inhibit RLS40 Lymphosarcoma Growth in Mice via Stimulation of Th1/Th17 Immune Response, in the Journal: Pharmaceutics 2022, 2542 of 23/05/2019
- what: The authors compare the antitumor potential of cell-free vaccines based on microvesicles derived from cells (DCs) with DC- and cationic-liposome-based vaccines using a murine model of drug . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.